Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Limited Stage Small Cell Lung Cancer 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 34Pemetrexed 27Drug Therapy 22Cisplatin 22osimertinib 18aflutinib 11Paclitaxel 11pembrolizumab 10Surgical Procedures, Operative 10Docetaxel 10tislelizumab 9Radiotherapy 8Magnetic Resonance Spectroscopy 8anlotinib 7Specimen Handling 7Bevacizumab 7130-nm albumin-bound paclitaxel 7toripalimab 6cemiplimab 6Immunotherapy 6sintilimab 5ensartinib 5durvalumab 5Radiosurgery 5Platinum Compounds 5Nivolumab 5trametinib 4aumolertinib 4Observation 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Non-Small-Cell Lung × trilaciclib × Clear all
NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

Sun Yat-sen University

Phase 2 Not yet recruiting
132 enrolled
BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡